Combined use of multikinase inhibitor
AssigneeTransthera Sciences (Nanjing), Inc.
InventorsPeng PENG, Xiaoyan QIANG, Frank WU
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition of a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, or a crystal form thereof with a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and a kit thereof and the use thereof in the treatment of cancer diseases, wherein Y, P, W and Ar are as defined in the specification.
Claims16
A pharmaceutical composition of a multi-kinase inhibitor compound shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof and a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody,
- wherein,
- Ar is selected from phenyl and 5-6 membered heteroaryl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
- Y is selected from CR3;
- P is selected from CR4;
- W is selected from N;
- R3 is selected from hydrogen and C1-4 alkyl;
- R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, oxa-C5-8 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C3-6 cycloalkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, —(CH2)n—C3-10 cycloalkyl, —(CH2)n-(5-11) membered heterocyclyl, and —(CH2)n-(5-10) membered heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.
A kit for treating a cancer, comprising (a) a multi-kinase inhibitor compound shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof, (b) a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and (c) a package insert,
- wherein,
- Ar is selected from phenyl and 5-6 membered heteroaryl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
- Y is selected from CR3;
- P is selected from CR4;
- W is selected from N;
- R3 is selected from hydrogen and C1-4 alkyl;
- R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, oxa-C5-8 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C3-6 cycloalkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, —(CH2)n—C3-10 cycloalkyl, —(CH2)n-(5-11) membered heterocyclyl, and —(CH2)n-(5-10) membered heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.
Dependencies are inferred from the claim text.